Last updated: November 6, 2026
Panhematin is an ultra-orphan hemin product used for acute attacks of acute intermittent porphyria, primarily in the United States. Its commercial profile is defined by a small diagnosed patient population, high treatment urgency, limited direct competition, and the absence of meaningful patent-based exclusivity. Recordati Rare Diseases controls the U.S. product following its acquisition of U.S. rights from Lundbeck. Public filings do not disclose Panhematin revenue separately, so the product’s financial trajectory must be assessed through market structure, treatment volumes, pricing, corporate portfolio disclosures, and competitive developments.
What is Panhematin and how does it generate revenue?
Panhematin is hemin for injection, supplied as a 350 mg single-dose vial for intravenous administration. It is FDA-approved for ameliorating recurrent attacks of acute intermittent porphyria in women when attacks are temporally related to the menstrual cycle. The FDA label does not establish efficacy for every acute porphyria subtype or for all causes of acute neurovisceral attacks. [1]
Panhematin is a conventional prescription drug approved under an NDA, not a biological product approved under a BLA. Hemin is a naturally occurring biological molecule, but Panhematin does not face biosimilar competition under the FDA biosimilar pathway.
| Attribute |
Panhematin |
| Active ingredient |
Hemin |
| Dosage form |
Sterile powder for injection |
| Strength |
350 mg per vial |
| Administration |
Intravenous infusion |
| U.S. approval pathway |
NDA |
| FDA approval |
1983 |
| Current U.S. commercial rights |
Recordati Rare Diseases |
| Primary indication |
Acute intermittent porphyria attacks |
| Product category |
Ultra-orphan drug |
| Direct U.S. competition |
Limited |
| Biosimilar exposure |
None |
| Main future substitution risk |
Generic hemin, 505(b)(2) product, or alternative acute-porphyria therapy |
Revenue is generated primarily through episodic hospital or specialty-pharmacy treatment rather than chronic daily use. A typical acute attack may require multiple vials, but dosing depends on patient weight, severity, response, and clinical practice.
Who owns Panhematin and how has the commercial platform changed?
Recordati Rare Diseases is the current U.S. commercial owner. Recordati obtained U.S. rights to Panhematin from Lundbeck as part of its expansion in rare diseases. The transaction increased Recordati’s exposure to rare metabolic and hematology products without requiring the company to develop a new molecule or obtain a new indication.
The ownership history matters because Panhematin’s value is based less on patent duration than on:
- U.S. regulatory approval;
- established physician familiarity;
- hospital procurement relationships;
- emergency availability;
- manufacturing and quality-control capability;
- reimbursement experience;
- a limited number of diagnosed patients.
Recordati reports financial results at company and segment levels. Public annual reports do not normally provide a separate Panhematin revenue line. As a result, there is no verified public annual-sales series for Panhematin comparable with publicly reported sales for major branded medicines. [2]
How large is the Panhematin market?
The Panhematin market is small in patient count but potentially high in revenue per treated episode. Acute hepatic porphyrias are rare, and acute intermittent porphyria is the most common form in many Western populations. Clinical penetrance is low: many genetically affected individuals do not develop recurrent symptomatic attacks.
The commercial market is limited by four factors:
- The number of diagnosed, symptomatic patients is small.
- Many patients are treated intermittently rather than continuously.
- Acute attacks may be managed initially with carbohydrate loading and supportive care.
- Treatment is concentrated in specialist centers and hospitals.
The product can still generate meaningful orphan-drug revenue because a single severe episode can require several high-value vials, and treatment decisions are driven by clinical urgency rather than routine price comparison.
Market demand is also uneven. Monthly menstrual-cycle-related attacks, recurrent hospitalizations, pregnancy-related management, and severe neurovisceral episodes create higher-utilization subgroups. Patients with infrequent attacks may produce little annual revenue, while recurrently hospitalized patients can generate substantially more.
What is Panhematin’s financial trajectory?
The public financial record supports a structural, not product-specific, assessment.
| Financial driver |
Effect on Panhematin |
| Ultra-orphan prevalence |
Limits total addressable volume |
| High treatment urgency |
Supports premium pricing and lower price sensitivity |
| Episodic dosing |
Creates volatile year-to-year revenue |
| No separate public sales disclosure |
Prevents verified product-level growth calculation |
| Established FDA approval |
Reduces regulatory development risk |
| Recordati rare-disease platform |
Supports specialty distribution and commercialization |
| Givlaari launch |
Creates a competing treatment option for recurrent disease |
| Limited direct competition |
Protects utilization in acute rescue treatment |
Panhematin’s revenue is likely more sensitive to patient identification, diagnosis rates, treatment protocols, and product availability than to broad pharmaceutical-market growth. Growth can occur through increased recognition of acute hepatic porphyria, better genetic testing, and greater use in emergency departments. Declines can result from prevention with Givlaari, improved diagnostic differentiation, hospital formulary restrictions, or substitution by another hemin product.
Recordati’s overall rare-disease business has expanded through acquisitions and commercial portfolio development, but corporate growth cannot be attributed to Panhematin without product-level disclosure. Panhematin should therefore be treated as a cash-generating niche asset rather than as a separately measurable growth franchise.
What competitive products affect Panhematin demand?
Givlaari
Givlaari, or givosiran, is an RNA interference therapy approved by the FDA in 2019 for adults with acute hepatic porphyria. It is administered chronically and is intended to reduce the frequency of attacks rather than treat an acute episode in the same way as hemin. [3]
The products occupy different treatment positions:
| Factor |
Panhematin |
Givlaari |
| Treatment role |
Acute attack management |
Preventive chronic therapy |
| Active ingredient |
Hemin |
Givosiran |
| Administration |
IV infusion |
Subcutaneous injection |
| Use pattern |
Episodic |
Regular ongoing dosing |
| FDA product type |
NDA drug |
New molecular entity |
| Primary commercial risk |
Generic or alternative hemin |
Payer access and high chronic-treatment cost |
| Effect on acute rescue demand |
Direct treatment |
May reduce future attack frequency |
Givlaari is the most important commercial competitor because successful prevention can reduce the number of acute attacks requiring Panhematin. It does not eliminate the need for rescue treatment in every patient, particularly when attacks occur before preventive therapy is initiated or despite treatment.
Hemin arginate and non-U.S. products
Hemin arginate, marketed as Normosang in several countries, is used internationally for acute porphyria attacks. Its availability, regulatory status, and reimbursement vary by jurisdiction. It is not interchangeable in every market from a regulatory or procurement perspective.
Outside the United States, Panhematin may face greater competition from hemin arginate and locally available products. Geographic access is therefore a material determinant of global commercial value.
Glucose and supportive care
High-carbohydrate treatment can be used in selected mild attacks or as initial management, although severe attacks generally require specialist evaluation and may require hemin. Supportive care does not represent a direct branded competitor but can reduce utilization in less severe cases.
When does Panhematin lose exclusivity?
Panhematin’s original market exclusivity has long expired. The product was approved in 1983, and any original patent and orphan exclusivity periods are no longer commercially relevant. There is no known current patent-based exclusivity period that prevents a competing hemin product from entering the U.S. market.
The main barriers are regulatory and operational rather than patent-based:
- demonstrating pharmaceutical equivalence or an appropriate alternative pathway;
- manufacturing sterile injectable hemin;
- establishing product quality and stability;
- satisfying FDA requirements for a complex injectable product;
- obtaining hospital and specialty-pharmacy acceptance;
- maintaining reliable supply during urgent demand.
What is the Orange Book status of Panhematin?
Panhematin is an NDA product, but its commercial protection is not understood to depend on a current Orange Book patent estate. The FDA Orange Book should be used to verify the current listing, any listed patents, and the status of approved ANDAs. [4]
Based on the product’s age and the absence of a publicly prominent active patent portfolio, the key regulatory question is whether an approved generic or competing hemin product exists, not whether a remaining composition-of-matter patent blocks entry.
A competitor could pursue an ANDA if it can demonstrate the required equivalence to the reference product. A 505(b)(2) application could become relevant if the proposed product differs in formulation, presentation, route, labeling, or supporting clinical framework.
Which companies are challenging Panhematin?
No prominent public Paragraph IV litigation campaign against Panhematin is identified in the principal public regulatory and patent records reviewed for this analysis. No major public settlement agreement involving a Paragraph IV challenge is identified.
The absence of visible litigation does not mean the product is insulated from entry. A generic manufacturer may have limited economic incentive to litigate before filing, particularly if the market is small and the reference product has no blocking patent. The more credible threat is a non-litigation launch by an approved competing product after regulatory approval.
Potential challengers would most likely include generic injectable manufacturers with experience in sterile powders, hospital products, and orphan-drug supply. The economic case depends on whether the entrant can achieve sufficient volume while maintaining manufacturing reliability.
How strong is the Panhematin patent estate?
Panhematin’s patent estate appears weak as a current exclusivity asset because the original approval dates to 1983 and no widely recognized active composition, formulation, or method-of-use patent is known to provide long-term market protection.
| Patent category |
Current commercial relevance |
| Original active-ingredient patent |
Expired or no longer relevant |
| Original product patent |
Expired or no longer relevant |
| New formulation patents |
No prominent active estate identified |
| Method-of-use patents |
No prominent blocking estate identified |
| Manufacturing patents |
Potentially useful as know-how, but not clearly disclosed as blocking rights |
| Orphan exclusivity |
Expired for the original product |
| Regulatory exclusivity |
No current long-duration exclusivity identified |
The strongest protection is practical know-how. Sterile injectable manufacturing, raw-material qualification, release testing, vial supply, and emergency distribution can create entry friction even without enforceable patent rights.
What generic launch scenarios exist?
Scenario 1: No near-term generic entry
This remains commercially plausible if the market is too small, manufacturing is difficult, or the expected price discount does not compensate for development and supply-chain costs. Panhematin would retain most of its acute-treatment volume.
Scenario 2: One approved generic
A single generic could reduce net pricing through hospital tenders and payer negotiations. The effect on total volume may be limited because acute episodes require immediate availability and physicians may continue using the established brand.
Scenario 3: Multiple generic entrants
Multiple suppliers could materially reduce price and compress Recordati’s revenue. This outcome would require sufficient market size to support several sterile-injectable manufacturers.
Scenario 4: Preventive-therapy substitution
Greater use of Givlaari could reduce attack frequency and lower annual Panhematin utilization without any generic entry. This is the most important non-patent erosion mechanism.
What manufacturing and intellectual-property barriers protect Panhematin?
The primary barrier is technical execution. Hemin products require control of identity, purity, sterility, potency, particulate matter, stability, and container closure. A product can be chemically well characterized while still presenting manufacturing and comparability challenges as a sterile injectable.
Commercial barriers also matter. Hospitals and emergency departments value predictable availability because delayed treatment can increase morbidity and length of stay. A new supplier must demonstrate dependable supply, appropriate distribution, and acceptable reimbursement handling.
These barriers support pricing power but do not create the legal exclusivity associated with an active patent or unexpired orphan designation.
What is the revenue exposure for Recordati?
Panhematin is unlikely to represent a large proportion of Recordati’s consolidated revenue because Recordati operates a diversified specialty and rare-disease portfolio. Its strategic value is higher than its likely share of group sales because it provides:
- recurring demand in a medically urgent setting;
- a differentiated orphan indication;
- an established commercial product;
- cross-selling and distribution leverage within rare diseases;
- limited direct branded competition.
The product’s downside exposure is concentrated in the U.S. market. A U.S. generic, a competing hemin product, or a significant shift toward preventive treatment could reduce revenue. Its upside is constrained by the small patient population and the fact that treatment is episodic.
Key Takeaways
- Panhematin is an ultra-orphan hemin product for acute intermittent porphyria attacks.
- It is an NDA drug, not a biologic, so biosimilar competition is not the relevant risk.
- Recordati Rare Diseases controls the U.S. commercial product after acquiring rights from Lundbeck.
- Public filings do not separately disclose Panhematin revenue, preventing a verified product-level financial growth rate.
- Original patent and orphan exclusivity have expired.
- The current moat is based on clinical familiarity, supply reliability, hospital access, and manufacturing know-how.
- Givlaari is the main competitive threat because prevention can reduce acute attacks.
- Generic risk is regulatory and manufacturing-driven rather than patent-driven.
- A single generic could pressure pricing; multiple entrants could materially erode revenue.
- Panhematin is strategically valuable as a niche rare-disease asset but is unlikely to be a major consolidated revenue driver for Recordati.
FAQs
Is Panhematin a biologic drug?
No. Panhematin contains hemin but is regulated as an NDA-approved drug rather than a BLA-approved biologic. Biosimilar substitution is therefore not the relevant market-access pathway.
Is Panhematin still protected by orphan-drug exclusivity?
No. The product was approved in 1983, and its original orphan exclusivity period has expired.
Does Givlaari replace Panhematin?
No. Givlaari is preventive therapy for acute hepatic porphyria, while Panhematin is used primarily to manage acute attacks. Givlaari may reduce future Panhematin demand but does not eliminate rescue-treatment requirements.
Why has a generic Panhematin not created major price erosion?
The market is small, demand is episodic, and sterile injectable manufacturing requires specialized capabilities. These factors can reduce the economic incentive for generic entry even when patent protection is absent.
Is Panhematin revenue reported separately by Recordati?
No separate Panhematin revenue line is generally provided in Recordati’s public financial reporting. Product-level revenue and margin estimates therefore cannot be verified from the company’s consolidated disclosures.
References
-
U.S. Food and Drug Administration. (n.d.). Panhematin (hemin for injection) prescribing information. FDA.
-
Recordati S.p.A. (2024). Annual report 2023. Recordati.
-
U.S. Food and Drug Administration. (2019). FDA approves first treatment for adults with acute hepatic porphyria. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA.
